The Drugs Controller General of India has conducted emergency use of Hetero’s Tocilizumab for treatment of hospitalized adults suffering covid-19.
ADVERTISEMENT
PTI reported, Hetero’s associate company Hetero Healthcare will market its biosimilar version of Tocilizumab under the brand name Tocira.
“This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the government to ensure equitable distribution.”, Hetero Group Chairman B Partha Saradhi Reddy said.
The drug Tocilizumab, which is a biosimilar version of ‘Roche’s Actemra’, would be available in the market by end of the September.
